Compare Lumen Technologies Inc (LUMN) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lumen Technologies Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Lumen Technologies Inc trades at $4.49 (market cap $5.14B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is the larger of the two by market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Lumen Technologies Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Lumen Technologies Inc for 40 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| LUMN | SYRE | |
|---|---|---|
Market Cap | $5.14B | $7.52B |
Volume | 15,538,010 | 1,441,031 |
Sector | Media | Health |
52-Week High | $11.83 | $108.92 |
52-Week Low | $4.55 | $22.18 |
Typical Hold Time | 40 Days | 0 Days |
Enterprise Value | $16.76B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LUMN stock trades at $4.55, down 9.9% in the past 24 hours, reflecting bearish technical signals and negative investor sentiment. The company reported mixed quarterly earnings, with a Q1 2026 miss but a Q2 2026 beat, while full-year 2025 revenue declined to $12.40B with a net loss of $1.74B. High debt levels and a negative ROE of -78.94% highlight financial strain, though recent strategic moves include a Nasdaq listing and new AI-focused networking services to drive growth.
The outlook remains challenging due to persistent losses and heavy debt, but deep value metrics like a low P/S of 0.42 and strategic pivots to AI connectivity offer speculative upside. Key risks include execution on growth initiatives, competitive pressures, and interest rate sensitivity. Analysts are largely cautious, with a 'Reduce' consensus, suggesting limited near-term catalysts.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
